Thus, the risk of recurrence of invasive breast cancer or of death was 60% lower with adjuvant trastuzumab emtansine than with trastuzumab alone among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy [95]. The gene discussed is ERBB2; the disease is breast cancer.